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Abstract: A large number of studies have indicated that thiazo-
lidinediones (TZDs) such as rosiglitazone and pioglitazone inhibit
tumor growth, progression, and metastasis. These agents are specific
agonists for the nuclear receptor peroxisome proliferator-activated
receptor- (PPAR) but also engage other pathways. In lung cancer,
these agents have been shown to induce apoptosis and inhibit tumor
growth in xenograft models. Retrospective studies have indicated a
significant decrease in lung cancer risk in patients using these
agents, suggesting that TZDs may be chemopreventive for lung
cancer. However, emerging data suggest that chronic use of these
agents is associated with increased risk of adverse cardiovascular
events. It is therefore critical to determine the relative contributions
of PPAR-dependent versus PPAR-independent pathways in me-
diating both the anti-tumorigenic effects and the cardiovascular
effects of TZDs. This review examines these pathways with a
specific focus on the role of TZDs and PPAR in lung cancer.
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Peroxisome proliferator-activated receptor- (PPAR) is amember of the nuclear-hormone-receptor superfamily and
was initially demonstrated to have important roles in lipid
metabolism and adipose differentiation.1 PPAR binds as a
heterodimer with the retinoic acid X receptor. These het-
erodimers, complexed with either co-activators or co-repres-
sors, bind to specific PPAR response elements in the pro-
moter regions of their target genes. PPAR is activated by
polyunsaturated fatty acids and eicosanoids, as well as by the
class of thiazolidinediones (TZDs). Binding of these agents
causes release of co-repressors and binding of co-activators,
resulting in changes in transcription of target genes. More
recently, activation of PPAR has been shown to involve
activation of protein kinases, which can phosphorylate
PPAR and modulate activity.2 Data from our lab and others
also indicate that direct binding of extracellular-regulated
kinase 5 (ERK5), a member of the mitogen-activated protein
kinase (MAP kinase) family, to the hinge region of PPAR
can regulate activity in a ligand-independent fashion.3,4
Activation of individual PPAR has been implicated in
many types of cancer, including breast, colon, and prostate.5
In lung cancer, several studies have demonstrated that TZDs
inhibit growth of non-small cell lung cancer (NSCLC) cells in
vitro.6–8 These studies have been extended to show that these
agents block tumor progression in a xenograft model.9 In
samples from human lung tumors, decreased expression of
PPAR was correlated with poor prognosis.10 A separate
study that examined expression of PPAR by immunohisto-
chemistry reported that well-differentiated adenocarcinomas
had a greater frequency of PPAR-positive cells than poorly
differentiated samples. Activation of PPAR has effects on
the tumor cells themselves but also affects production of a
subclass of cytokines having the amino terminal sequence
Glu-Leu-Arg (ELR cytokines), which are critical for an-
giogenesis and tumor-stromal interactions.11 Our data indi-
cate that PPAR activation has selective effects on differen-
tiation and metastasis of NSCLC.12
A recent retrospective study demonstrated a 33% re-
duction in lung cancer risk among patients with diabetes
using the TZD rosiglitazone.13 An even more dramatic re-
duction was observed among African-American patients
(75%). This decreased risk seemed to be specific for lung
cancer, and no protective effect was observed for prostate or
colon cancer. Further studies need to be performed in this
area, and conflicting effects of TZDs on susceptibility to
other types of cancer have been reported.14,15
“ON-TARGET” VERSUS “OFF-TARGET” EFFECTS
OF TZDS
These findings suggest that TZDs such as rosiglitazone
may have chemoprotective affects against the development of
lung cancer. However, several recent reports have indicated
that patients with diabetes receiving rosiglitazone had a
significantly higher risk of adverse cardiovascular events,
including myocardial infarctions,16 mitigating against chronic
use of this class of agents. A critical issue is therefore
determining whether the effects of TZDs in inhibiting lung
cancer initiation and progression are mediated through
PPAR-dependent versus PPAR-independent pathways
(Figure 1). Investigators have begun to address these issues
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by comparing the responses of cells to TZDs with overex-
pression of full-length PPAR. In NSCLC, overexpression of
PPAR did not have significant effects on cell proliferation,
as seen with TZD treatment, but it had selective effects on
anchorage-independent growth and invasiveness.12 Han and
coworkers reported that activation of AMPK occurs in re-
sponse to rosiglitazone but that this was not seen in NSCLC
overexpressing PPAR.17
Pathways that are activated by TZDs in a PPAR-
independent fashion have been identified. A subset of
NSCLC produces high levels of prostaglandin E2 (PGE2) as
a consequence of induction of cyclooxygenase 2 (COX-2).
Increased PGE2 promotes tumor growth and progression
through a number of pathways, and COX-2 inhibitors are
currently in clinical trials for NSCLC.18 Rosiglitazone inhib-
its PGE2 production in a subset of NSCLC, but this is
mediated through induction of 15-hydroxyprostaglandin de-
hydrogenase, the enzyme that metabolizes PGE2.19 Activa-
tion of tumor necrosis factor-related apoptosis-inducing li-
gand (TRAIL)-induced apoptosis by TZDs has been shown to
be mediated through a PPAR-independent induction of
death receptor-5 (DR5) and down-regulation of c-FLIP in
NSCLC cell lines.20 Troglitazone induces apoptosis in
NSCLC through both “on-target” and “off-target” pathways
and activates the ERKMAP kinase family in NSCLC through
a PPAR-independent pathway.21 A separate study demon-
strated that this agent can also induce expression of the
immediate early gene egr-1 through a PPAR-independent
mechanism.22 A number of these studies have used pharma-
cological inhibitors to assess whether a TZD is signaling
through PPAR-dependent mechanisms.17 Care must be
taken in interpreting data with these agents, because they, like
TZDs themselves, are likely to engage multiple pathways
distinct from PPAR.
Genetic studies have used cells derived from PPAR-
deficient mice. In macrophages derived from PPAR knock-
out mice, both TZDs and the physiologic PPAR activator
15-deoxy-12,14-prostaglandin J2 (dPGJ2) inhibited release
of cytokines to the same extent as in wild-type macro-
phages.23 PPAR activators also inhibited growth of embry-
onic stem cells from PPAR null mice via a mechanism that
involves inhibition of translation.24 Activation of NF-B by
dPGJ2 was also observed in PPAR-deficient cells.25 Because
homozygous deletion of PPAR is embryolethal, validating
FIGURE 1. Thiazolidinediones (TZD), such as rosiglitazone and pioglitazone, can act by directly binding to the ligand-bind-
ing domain of PPAR, which forms a dimer with the retinoic acid X receptor (RXR), which binds retinoic acid (RA). This het-
erodimer recognizes characteristic regulatory elements in the promoters of target genes, for which the conensus is a direct
repeat of the sequence AGGTCA separated by a single nucleotide (N). Binding of TZDs causes a conformational change that
results in displacement of co-repressors, such as nuclear receptor co-repressor (NCoR) and silencing mediator of retinoic acid
and thyroid hormone receptor (SMRT), and binding of co-activators such as p300 and steroid receptor co-activator (SRC),
leading to enhanced transcription. These agents engage other effectors through “off-target” mechanisms that remain to be
identified. These pathways potentially include induction of 15-hydroxyprostaglandin dehydrogenase, which degrades prosta-
glandins such as prostaglandin E2 (PGE2), which is produced at high levels in many non-small cell lung cancer cells. De-
creased production of PGE2 inhibits tumor progression by increasing expression of E-cadherin, resulting in enhanced epithelial
differentiation. TZDs can also lead to activation of tumor-necrosis factor (TNF) and the transcription factor NF-B, which pro-
motes apoptosis. Separate studies demonstrated that TZDs can also induce apoptosis through TNF-related apoptosis-inducing
ligand (TRAIL)-dependent pathways.
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the role of PPAR in responses of lung cancer cells to TZDs
will require approaches such as siRNA silencing.
FUTURE DIRECTIONS
Defining the off-target effects of TZDs such as rosigli-
tazone will be critical in developing new therapeutic agents.
In particular, it will be important to determine whether the
adverse cardiovascular effects of these agents are mediated
through PPAR-dependent or -independent mechanisms. If
the deleterious effects of TZD on the cardiovascular system
are mediated through PPAR-independent effects, then the
development of second-generation, more specific PPAR
activators may provide more selective engagement of
PPAR-dependent anti-tumorigenic effects and minimize the
adverse cardiovascular effects. Conversely, if the adverse
cardiovascular effects are indeed mediated through PPAR-
dependent mechanisms, then more selective targeting of
PPAR activators to tumors will be required. Alternatively,
defining downstream effector pathways of PPAR may de-
fine novel therapeutic targets. Similar problems have arisen
with the clinical use of COX-2 inhibitors. Long-term use of
these agents has also been associated with increased risk of
cardiovascular complications. In the case of COX-2 inhibi-
tors, this has been attributed to inhibition of COX-2–medi-
ated production of prostacyclin, which is cardioprotective.26
Because PPAR can inhibit prostaglandin production through
both COX-2–dependent and COX-2–independent path-
ways,19,27,28 it is tempting to speculate that the cardiovascular
toxicity of TZDs may also involve inhibition of prostacyclin
production. Interestingly, prostacyclin itself has been shown
to activate PPAR isoforms. Whereas most studies have im-
plicated PPAR as a direct target for prostacyclin,29 our data
suggest that prostacyclin analogs such as iloprost can also
engage PPAR in lung cells. Thus, administration of prosta-
cyclin analogs, may provide alternatives to TZDs and, in
addition to activating PPAR, will mediate cardioprotective
effects, potentially removing the negative cardiovascular ef-
fects seen with TZDs.
Finally, it should be stressed that more studies are
required to define the downstream effectors of PPAR that
mediate the antitumorigenic effects in NSCLC. Because
PPAR is a ligand-activated transcription factor, the direct
targets should be genes whose expression is altered as a
consequence of TZDs binding to PPAR-retinoic acid X
receptor heterodimers. Expression profiling of NSCLC ex-
posed to TZDs, followed by examination of promoter regions
of target genes and validation by quantitative PCR and
chromatin immunoprecipitation, will be critical in establish-
ing PPAR-dependent pathways.
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